PCM
PRLD icon

Prelude Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Prelude Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,074
Closed -$42.2K – 1494
2024
Q2 		$42.2K Sell
11,074
-2,772
-20% -$11.3K ﹤0.01% 1156
2024
Q1 		$65.6K Sell
13,846
-500
-3% -$1.95K ﹤0.01% 1237
2023
Q4 		$61.3K Buy
+14,346
New +$43.7K ﹤0.01% 1064

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Prelude Capital Management's PRLD Position: Q3 2024 in Review

Prelude Capital Management sold out of Prelude Therapeutics (PRLD) in Q3 2024, closing a stake of 11,074 shares — an estimated $42.2K sold.

Prelude Capital Management first reported a position in PRLD in Q4 2023 and held it in 3 quarters. The position peaked at $65.6K in Q1 2024. 70 funds tracked by Wall St. Rank hold PRLD as of Q3 2024.

  • Prelude Capital Management reported no remaining Prelude Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Prelude Capital Management sold 11,074 Prelude Therapeutics shares in Q3 2024, an estimated $42.2K.
  • Prelude Capital Management first reported a position in Prelude Therapeutics in Q4 2023 and held it in 3 quarters.
  • Prelude Capital Management's Prelude Therapeutics position peaked at $65.6K in Q1 2024.
  • 70 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q3 2024.

Based on Prelude Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.